Stock screenerAll disclosures →
EDGAR →
INBX
Conviction 67HealthcareScan · Thu, Jun 25, 2026INBX$94.91-0.25%
ResistanceSupportVol 14Vol MA14 331.53K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price94.91
Change-0.25%
Gap+0.97%
Rel volume1.26×
Avg volume327.73K
Avg $ vol30.73M
SMA 2093.90
SMA 50105.82
SMA 20076.38
Price vs 50-10.32%
Price vs 200+24.25%
MA stackmixed
50/200 cross—
Supertrenddown · 114.37
RSI (14)47
MACD hist0.69
MACD crossbull · 4d
Stoch %K / %D68 / 64
ADX (14)20
+DI / −DI11 / 17
RSI divergence—
MACD divergenceBullish
ATR %+8.11%
ADR %6.86%
52w high141.84
52w low14.27
From 52w high-33.09%
Above 52w low+565.07%
New 52w highNo
SqueezeOn · 4d
Bollinger width18.15%
%B0.56
Donchian pos47.29%
Donchian high105.41
Donchian low85.48
AVWAP (52w high)113.76
vs AVWAP high-16.57%
AVWAP (52w low)77.97
vs AVWAP low+21.71%
OBV trendFlat
Chaikin MF (20)-0.08
Today vs 20d1.26×
Avg vol (14d)331.53K
Avg vol (20d)327.73K
Avg $ vol (20d)30.73M
Market cap1.39B
RS 3m (vs SPY)+38.47%
RS 6m (vs SPY)+2.72%
RS line new highNo
Trend template6/8
Technical rank62.3
1 week+0.75%
1 month-11.18%
3 months+42.80%
6 months+8.44%
1 year+542.99%
YTD+26.47%
P/E-9.94
P/B-66.19
P/S—
P/FCF-10.72
EPS-9.04
Div yield—
ROE665.82%
ROA-76.13%
Debt/Eq-8.32
Current6.46
EV/EBITDA-10.61
Gross margin—
Net margin—
Rev growth550.00%
EPS growth-108.30%
Price target277.50
Target upside192.40%
Analyst ratingBuy
Institutional92.07%
Ent. value1.41B
Revenue0
Net income-33.44M
Gross profit—
Free cash flow-129.82M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out14.67M
Employees110
ListedTue, May 28, 2024
Free float7.71M
Float %53.0%
Short interest3.18M
Days to cover9.3d
Short volume78.4%
Squeeze score89 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$2.15 vs −$2.37
Last surprise+9.3% beat
Setup gradeB
Conviction67 / 100
Pattern quality—
Tech rank62.3 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance146.55
Support85.94
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in INBX
No recent disclosed trades by Congress in INBX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in INBX · 5 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
MANHARD KIMBERLY Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Kayyem Jon Faiz Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Vuori Kristiina MD Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
FORSYTH DOUGLAS Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Matly David President · Stock Option (right to buy) · 2026-04-24 | Grant | 50K | $0 | 2026-04-24 | 2026-04-27 |
SEC filings
EDGAR filings in INBX · 2 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.